Tiger pharmaceutical performance forecast: net profit in 2020 will increase by 100% - 115% year on year

Clinical CRO Tigermed: The ‘Small and Beautiful’

In this race of pharmaceutical R&D outsourcing segment, WuXi AppTec, Pharmaron, Tigermed and Asychem are some of the major names – but which has a truly winning side?

Haier Biomedical 'Smart Blood City Network' Lands in Brazil

Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.

CRO ClinChoice Raises USD 150 Mn in Series E Round

2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.

CRO Giant Tigermed’s 1H 2020 Net Profits Up 98%

Chinese CRO industry is setting off – the continued pandemic may bring the most potential to this industry.

WuXi AppTec: A Favorable Chinese Stock for MSCI and FTSE Russell

According to the latest quarterly index review, a Wuxi-based CRO company will be incorporated into the FTSE China A 50 Share Index.  It has been considered a top holding by many MSCI China indexes for some time.